BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ICON Awarded Phase I Supplementary Accreditation from Medicines and Healthcare Products Regulatory Agency


10/6/2010 1:10:01 PM

DUBLIN, 6th October, 2010: ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that its hospital-based Clinical Pharmacology Unit in Manchester, UK has achieved Supplementary Accreditation from the Medicines and Healthcare products Regulatory Agency (MHRA).The purpose built unit, part of the ICON Development Solutions division, is situated on the largest academic healthcare campus in Europe.

Supplementary Accreditation is the highest level of accreditation in Europe - going beyond Standard Accreditation to demonstrate that ICON’s Clinical Pharmacology Unit adheres to the highest clinical safety standards. This designation permits ICON to carry out all Phase I trials including First in Human (FIH) trials requiring review from the EAG (Expert Advisory Group).

Thomas Frey, President ICON Development Solutions, commented: “Our Clinical Pharmacology team in Manchester worked closely with the MHRA during their routine inspection to demonstrate our active commitment to safety and quality. This accreditation award, combined with our experience conducting over 1,500 early phase studies, reinforces to trial volunteers and sponsors alike that ICON is an industry-leader in Phase I clinical research. We are pleased to have participated in this voluntary accreditation process that ensures continuous safety improvements are realised in early clinical development.”

The MHRA established this accreditation scheme in 2006 to formalise routine, rigorous inspections so that clinical safety standards are made even more robust. Accreditation is granted following a successful MHRA GCP Inspection where a unit must demonstrate appropriately trained personnel and facilities are immediately available to manage medical emergencies.

About ICON plc

: ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programmes that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has around 7,700 employees, operating from 71 offices in 39 countries.

Contact Details: Emily Brand Corporate Communications Manager +353-1-2912665 Emily.brand@iconplc.com

Sam Barnes Director Weber Shandwick | Healthcare Fox Court 14 Gray’s Inn Road London, WC1X 8WS t: +44 (0) 020 7067 0216 f: +44 (0) 844 875 1463 m: +44 (0) 7894 094 461

sbarnes@webershandwick.com www.webershandwick.co.uk



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES